Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

2263 PWToday Stories

Boston Scientific Announces Acquisition of EMcision, Limited

08 Mar 18

Boston Scientific (NYSE: BSX) today announced that it has acquired EMcision, Limited, a privately held company located in the United Kingdom and Canada. The acquisition will expand the Boston Scientific Endoscopy portfolio to include the HabibTM EndoHPB probe, a novel endoscopic bipolar radiofrequency device, which coagulates tissue in the gastrointestinal (GI) tract. The Habib EndoHPB probe is used by physicians in the treatment and palliative care of patients living with pancreaticobiliary cancers.

Patients with pancreaticobiliary cancers often develop jaundice as a result of tissue ingrowth that blocks ducts that enable bile to drain out of the GI tract. The Habib EndoHPB probe coagulates this tissue to help ensure that the fluids are able to drain, which can result in an improvement in a patient's quality of life. In addition to coagulating tissue, physicians will frequently place stents to ensure that the GI tract remains open during palliative care. 

"As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today," said Art Butcher, senior vice president and president, Endoscopy, Boston Scientific. "We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract." 

Pancreaticobiliary cancers account for nearly a million deaths annually worldwide and have limited treatment options.1 While an early diagnosis improves the likelihood that a patient can meet the criteria for surgical removal of a tumor,2 currently only 40 percent of patients with cholangiocarcinoma and 20 percent of patients with pancreatic cancer are candidates for surgery.3,4 The EMcision products have helped thousands of patients worldwide with these difficult to treat cancers for whom surgery is not an option.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.